Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings

ZVRA·Reported November 12, 2024·After market close

Zevra Therapeutics, Inc. reported Q3 2024 revenue of $3.7M, missed analyst consensus of $8.8M by $5.1M. Diluted EPS came in at $-0.69, missed the $-0.44 consensus by $0.25.

Revenue

$3.7Mmissed by $5.1M

Consensus: $8.8M

Diluted EPS

$-0.69missed by $0.25

Consensus: $-0.44

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001437749-24-034916

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q3 2024 Earnings FAQ

Common questions about Zevra Therapeutics, Inc.'s Q3 2024 earnings report.

Zevra Therapeutics, Inc. (ZVRA) reported Q3 2024 earnings on November 12, 2024 after market close.

Zevra Therapeutics, Inc. reported revenue of $3.7M and diluted EPS of $-0.69 for Q3 2024.

Revenue missed the consensus estimate of $8.8M by $5.1M. EPS missed the consensus estimate of $-0.44 by $0.25.

You can read the 10-Q periodic report (0001437749-24-034916) directly on SEC EDGAR. The filing index links above go to sec.gov.